AgomAb Therapeutics NV

Najnowszy kwartał, jaki mamy dla spółki AgomAb Therapeutics NV

Z własnego raportu 6-K spółki.

Co powiedział zarząd

“In the first half of 2026, we continued to execute on our clinical and operational strategy, and we are on track with the clinical read-outs and trial initiations of ontunisertib and AGMB-447 expected later this year,”

Cytowane dosłownie z komunikatu i pokazywane tylko wtedy, gdy raport przypisuje wypowiedź konkretnej osobie.

Czym zajmuje się AgomAb Therapeutics NV

Crohn’s Disease Crohn’s disease is a chronic progressive disease of the gastrointestinal tract. It is estimated that approximately 46% of patients with Crohn’s disease have fibrosis of the gastrointestinal tract, resulting in stricture formation and intestinal obstructions, most frequently in the terminal ileum. These strictures can cause obstructive symptoms leading to dietary change, malnutrition and surgery. Despite the large unmet medical need, there are no approved pharmacological therapies for FSCD.

Własny opis spółki, tak jak widnieje na końcu komunikatu.